Medtronic PLC said the U.S. Food and Drug Administration approved its Guardian monitoring system, which alerts diabetes patients of potential high or low glucose events up to 60 minutes in advance.
The glucose monitoring system is approved for diabetes patients 14-75 years old.
The Dublin-based medical device maker said its product will be available in the first quarter of fiscal 2019.
